193 related articles for article (PubMed ID: 29563911)
1. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
Front Immunol; 2018; 9():335. PubMed ID: 29563911
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.
Ersching J; Hernandez MI; Cezarotto FS; Ferreira JD; Martins AB; Switzer WM; Xiang Z; Ertl HC; Zanetti CR; Pinto AR
Virology; 2010 Nov; 407(1):1-6. PubMed ID: 20797754
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
Zheng X; Rong X; Feng Y; Sun X; Li L; Wang Q; Wang M; Liu W; Li C; Yang Y; Zhou R; Lu J; Feng L; Chen L
Emerg Microbes Infect; 2017 Jun; 6(6):e43. PubMed ID: 28588291
[TBL] [Abstract][Full Text] [Related]
6. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
Fitzgerald JC; Gao GP; Reyes-Sandoval A; Pavlakis GN; Xiang ZQ; Wlazlo AP; Giles-Davis W; Wilson JM; Ertl HC
J Immunol; 2003 Feb; 170(3):1416-22. PubMed ID: 12538702
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of Human Adenovirus Type 5 Neutralizing Antibody in Common Marmosets Determined by a New Set of Two Assays.
Wang Q; Sun Y; Xu Y; Wang Y; Wang H; Fu Y; Allain JP; Li C; Li T
Viral Immunol; 2019 Oct; 32(8):348-354. PubMed ID: 31433272
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.
Chen H; Xiang ZQ; Li Y; Kurupati RK; Jia B; Bian A; Zhou DM; Hutnick N; Yuan S; Gray C; Serwanga J; Auma B; Kaleebu P; Zhou X; Betts MR; Ertl HC
J Virol; 2010 Oct; 84(20):10522-32. PubMed ID: 20686035
[TBL] [Abstract][Full Text] [Related]
10. A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis.
Wang C; Dulal P; Zhou X; Xiang Z; Goharriz H; Banyard A; Green N; Brunner L; Ventura R; Collin N; Draper SJ; Hill AVS; Ashfield R; Fooks AR; Ertl HC; Douglas AD
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006870. PubMed ID: 30372438
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China.
Jian L; Zhao Q; Zhang S; Huang W; Xiong Y; Zhou X; Jia B
Arch Virol; 2014 Mar; 159(3):465-70. PubMed ID: 24057756
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus.
Zhi Y; Figueredo J; Kobinger GP; Hagan H; Calcedo R; Miller JR; Gao G; Wilson JM
Hum Gene Ther; 2006 May; 17(5):500-6. PubMed ID: 16716107
[TBL] [Abstract][Full Text] [Related]
15. Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
Nébié I; Edwards NJ; Tiono AB; Ewer KJ; Sanou GS; Soulama I; Sanon S; Diarra A; Yaro JB; Kangoye D; Imoukhuede EB; Hill AV; Sirima SB
Clin Vaccine Immunol; 2014 Jun; 21(6):901-3. PubMed ID: 24739980
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Pre-Existing Neutralizing Antibody to Human Adenovirus Types 5 and 49 and Simian Type 23 in Chinese Population.
Zou P; Wang Q; Zhang P; Luo S; Wang C; Zhang E; Zhang L; Li C; Li T
Viral Immunol; 2023 Nov; 36(9):617-625. PubMed ID: 37903228
[TBL] [Abstract][Full Text] [Related]
17. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
Dicks MD; Spencer AJ; Edwards NJ; Wadell G; Bojang K; Gilbert SC; Hill AV; Cottingham MG
PLoS One; 2012; 7(7):e40385. PubMed ID: 22808149
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
[TBL] [Abstract][Full Text] [Related]
20. Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon.
Su X; Tian X; Jiang Z; Ma Q; Liu Q; Lu X; Zhou R
PLoS One; 2016; 11(6):e0156984. PubMed ID: 27328032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
